Pangene is a privately
held genomics-based pharmaceutical drug company commercializing DNA
repair drugs and genomic services. Pangene uses its proprietary DNA
repair enzyme mediated platform to isolate, clone, express, drug
profile, and determine the functions of genes and their homologs.
Pangene's technology platform enables determination of gene dysfunction
underlying disease and development of pharmaceutical drugs. Pangene
discovered and patented the major human DNA repair genes and high value
DNA repair enzyme targets which enabled the development of Repair
Regulator Pharmaceutical Drugs (RRPDs) for radio-resistant or
chemo-resistant tumors. RRPDS are conveniently formulated for use in
combination with conventional
cancer therapies for more effective treatments of chemotherapeutic drug
resistant and radiation resistant skin, breast, ovarian, colon, brain,
prostate, pancreatic, head and neck and other tumors. The company
operates in state-of-the-art facilities with full capabilities for drug
development and genomic services. |
